open access

Vol 2, No 1 (2011)
Review paper
Published online: 2011-03-24
Get Citation

Optimization and individualization of treatment based on interim PET result in patients with Hodgkin lymphoma

Jan Maciej Zaucha
Hematologia 2011;2(1):15-22.

open access

Vol 2, No 1 (2011)
REVIEW ARTICLES
Published online: 2011-03-24

Abstract

Classification of Hodgkin lymphoma (HL) into 2 types: nodular and classical that is divided in the other 4 subtypes do not adequately reflect the diversity of this disease in terms of biology. This reflects well the imperfect classification of patients into 3 clinical groups with different prognosis and the lack of satisfactory options for treatment individualization. As a consequence, there are different standards of treatment, especially in patients with high risk factors. Treatment with BEACOPPesc program allows achieving long-lasting remission in nearly 90% of patients, but is hampered by significant early and late toxicity. Tolerance of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) is better, but sustained response is achieved only in 70% of patients. There is now some data suggesting that interim positron emission tomography (PET) combined with computed tomography (CT) in patients with HL predicts response to the standard ABVD treatment. A positive interim PET result indicates a treatment failure and the need for the treatment intensification. Retrospective studies demonstrate the effectiveness of this approach and encourage conducting prospective clinical studies verifying the effectiveness of interim PET to optimize therapy in patients with early and advanced form of HL.
Hematologia 2011; 2, 1: 15–22

Abstract

Classification of Hodgkin lymphoma (HL) into 2 types: nodular and classical that is divided in the other 4 subtypes do not adequately reflect the diversity of this disease in terms of biology. This reflects well the imperfect classification of patients into 3 clinical groups with different prognosis and the lack of satisfactory options for treatment individualization. As a consequence, there are different standards of treatment, especially in patients with high risk factors. Treatment with BEACOPPesc program allows achieving long-lasting remission in nearly 90% of patients, but is hampered by significant early and late toxicity. Tolerance of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) is better, but sustained response is achieved only in 70% of patients. There is now some data suggesting that interim positron emission tomography (PET) combined with computed tomography (CT) in patients with HL predicts response to the standard ABVD treatment. A positive interim PET result indicates a treatment failure and the need for the treatment intensification. Retrospective studies demonstrate the effectiveness of this approach and encourage conducting prospective clinical studies verifying the effectiveness of interim PET to optimize therapy in patients with early and advanced form of HL.
Hematologia 2011; 2, 1: 15–22
Get Citation

Keywords

Hodgkin lymphoma; interim PET

About this article
Title

Optimization and individualization of treatment based on interim PET result in patients with Hodgkin lymphoma

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 1 (2011)

Article type

Review paper

Pages

15-22

Published online

2011-03-24

Bibliographic record

Hematologia 2011;2(1):15-22.

Keywords

Hodgkin lymphoma
interim PET

Authors

Jan Maciej Zaucha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.